Analyzing R&D Budgets: Bristol-Myers Squibb Company vs Rhythm Pharmaceuticals, Inc.

R&D Spending: Giants vs. Innovators in Pharma

__timestampBristol-Myers Squibb CompanyRhythm Pharmaceuticals, Inc.
Wednesday, January 1, 201445340000005280000
Thursday, January 1, 201559200000007148000
Friday, January 1, 2016494000000019594000
Sunday, January 1, 2017641100000022894000
Monday, January 1, 2018634500000050337000
Tuesday, January 1, 20196148000000109450000
Wednesday, January 1, 20201114300000090450000
Friday, January 1, 202110195000000104128000
Saturday, January 1, 20229509000000108630000
Sunday, January 1, 20239299000000134951000
Monday, January 1, 202411159000000
Loading chart...

Data in motion

A Decade of Innovation: R&D Spending in Pharmaceuticals

Bristol-Myers Squibb vs. Rhythm Pharmaceuticals

In the ever-evolving world of pharmaceuticals, research and development (R&D) is the lifeblood of innovation. Over the past decade, Bristol-Myers Squibb Company and Rhythm Pharmaceuticals, Inc. have demonstrated contrasting approaches to R&D investment. Bristol-Myers Squibb, a titan in the industry, has consistently allocated substantial resources, with R&D expenses peaking at approximately $11 billion in 2020. This represents a remarkable 145% increase from 2014. In contrast, Rhythm Pharmaceuticals, a smaller player, has shown a steady yet modest growth in R&D spending, culminating in a 25-fold increase from 2014 to 2023. This disparity highlights the diverse strategies within the industry, where established giants and emerging innovators both play crucial roles. As we look to the future, these investments will undoubtedly shape the next wave of medical breakthroughs.

Published by
U.S. Securities and Exchange Commission

Source link
sec.gov

Date published
17 Jan 2025